MONTREAL, QUEBEC–(Marketwired – Aug 12, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has invested $1 million in the Bloom Burton Healthcare Lending Trust II (the “Trust”) managed by Stratigis Capital Advisors Inc. as part of a minimum $5 million private placement. The Trust will use the proceeds to invest in debt and debt-like securities of emerging commercial-stage public and private Canadian healthcare companies that have been overlooked by traditional lenders. In July 2015, Knight invested $500,000 in the Trust’s predecessor, the Bloom Burton Healthcare Lending Trust, which has performed well to date.

“Knight is pleased to lend a hand in support to Bloom Burton, who is, next to Knight, widely regarded as Canada’s leading source of deal-flow in the healthcare sector,” said Jonathan Ross Goodman, President and CEO of Knight. “We expect that this new investment will provide a GUD return and lead to additional secured lending opportunities with product rights for Knight.”

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at or

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.